Pathogenic RAD51C variants contribute to breast cancer risk, and elevated RAD51 levels in cell lines and primary tumors suggest that driving the HR pathway beyond physiological levels may also play a role in genomic instability and hence tumor progression [14, 210]. This evidence concerns the gene RAD51 and breast cancer.